WCP
UTHR icon

Wick Capital Partners’s United Therapeutics UTHR Stock Holding History

Wick Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Sell
377
-61
-14% -$34.4K 0.03% 236
2026
Q1 		$260K Sell
438
-172
-28% -$85.7K 0.05% 178
2025
Q4 		$297K Buy
+610
New +$284K 0.05% 144

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Wick Capital Partners's UTHR Position: Q2 2026 in Review

Wick Capital Partners reduced its United Therapeutics (UTHR) stake by 14% in Q2 2026, selling an estimated $34.4K and leaving 377 shares worth $204K. The position accounts for 0.03% of the portfolio, ranked #236.

Wick Capital Partners first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $297K in Q4 2025. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Wick Capital Partners held 377 shares of United Therapeutics worth $204K as of Q2 2026.
  • Wick Capital Partners sold 61 United Therapeutics shares in Q2 2026, an estimated $34.4K.
  • United Therapeutics made up 0.03% of Wick Capital Partners's portfolio in Q2 2026, its #236 holding.
  • Wick Capital Partners first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Wick Capital Partners's United Therapeutics position peaked at $297K in Q4 2025.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Wick Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.